U.S. Markets open in 25 mins

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.23+1.59 (+3.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.64
Open45.76
Bid41.69 x 800
Ask0.00 x 800
Day's Range45.20 - 47.25
52 Week Range42.19 - 125.00
Volume759,316
Avg. Volume1,000,034
Market Cap1.556B
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
    Zacks

    Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Intercept (ICPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Barrons.com

    Biogen Stock Is Jumping. The Biotech Submitted Its Troubled Alzheimer’s Drug for FDA Approval.

    Biogen has finished submitting its application for approval for aducanumab to the Food and Drug Administration. That submission was originally expected to be completed in early 2020.

  • FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval
    TipRanks

    FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval

    No pain, no gain goes the well-worn axiom. A stock market themed inverse can read: no gain, shareholder pain. You can currently apply the latter to Intercept Pharmaceuticals (ICPT). The small-cap biotech was hoping to gain the FDA’s nod of approval for its liver disease therapy, but there was only pain to endure, as the NDA was rejected. As a result, shares were sent tumbling by 40% on Monday June 29. So, what happened exactly? ICPT received a CRL from the FDA regarding its obeticholic acid (OCA) treatment in advanced-stage non-alcoholic steatohepatitis (NASH), due to a lack of evidence showing that the benefits of the treatment outweigh the potential risks. The FDA recommended that data from the ongoing Phase 3 REGENERATE study be further analyzed. NASH is a fatty liver disease, closely related to obesity, for which there are currently no specific drugs available. Due to the rising obesity rates, the market for NASH medications is expected to grow considerably over the next few years, with some estimates putting its worth at $35 billion. Intercept’s application was based on data from the treatment of over 1,700 NASH patients across 35 clinical trials. Management expects to schedule a meeting with the FDA in 2H20 to discuss how to move forward. Needham analyst Alan Carr expects the NDA to be resubmitted before the end of the year, and anticipates “the drug will be approved in the U.S. by mid-2021.” The analyst believes the rejection might have more to do with the current macro climate than with the data itself. Carr said, “We acknowledge the FDA clearly has some level of concern w/ OCA, however, we believe COVID-19 has played a role in disrupting and preventing completion of the review process. We await the outcome of the meeting with the FDA and assume resubmission by YE20. We still believe OCA will be approved in NASH, but have reduced our target due to launch delay.” That price target is slashed from $150 to $100, although the figure still implies hefty upside potential of 115%. Carr made no change to the rating, which remains a Buy. (To watch Carr’s track record, click here) Looking at the consensus breakdown, based on 6 Buys and 15 Holds, ICPT has a Moderate Buy consensus rating. With an average price target of $66.10, the analysts forecast possible upside of 42% over the next 12 months. (See Intercept price targets and analyst ratings on TipRanks)